Alan Alda says the first Parkinson’s symptom that he experienced ‘was not that well-known’ at the time, adding that he had ...

Alan Alda opens up about Parkinson’s disease in a new interview, sharing, ‘It’s not who I am.’ ...

Alan Alda publicly revealed he is suffering from Parkinson's in 2018, three and a half years after receiving his diagnosis.

Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...

Researchers engineered a lipid nano-emulsion from solid myristic acid and liquid palm oil that encapsulates L-DOPA in sub-100-nanometer particles and releases the drug slowly across stomach and ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Alan was 79 when he experienced his first - and uncommon - symptom, REM Sleep Behaviour Disorder (RBD). Cleveland Clinic says can be an early sign of a neurological condition, with "most people with ...

Fox was promoted to the companion level of the Order of Canada for his work through the Michael J. Fox Foundation, which has ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

Researchers at CSIR-Centre for Cellular and Molecular Biology (CCMB) have found possible links between RNA viruses like ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...